Zydus Lifesciences

齐杜斯生命科学

plans to acquire US-based

计划收购美国的

Agenus Inc

阿格诺斯公司

’s

的

biologics manufacturing

生物制品制造

facilities in California, a deal which will mark the Indian pharma company’s entry into the global biologics contract development and manufacturing sector.

加利福尼亚的设施，这笔交易将标志着这家印度制药公司进入全球生物制品合同开发和制造领域。

Zydus will acquire two biologics manufacturing facilities from Agenus at Emeryville and Berkeley in California for an upfront consideration of $75 million and a contingent payment of $50 million, to be paid over three years subject to achievement of certain revenue milestone, the Ahmedabad-based company said in a news release..

Zydus将斥资7500万美元收购Agenus位于加利福尼亚州埃默里维尔和伯克利的两个生物制品制造工厂，并在三年内支付5000万美元的或有款项，这笔款项取决于是否达到特定的收入里程碑，总部位于艾哈迈达巴德的公司在新闻稿中表示。

Agenus is a clinical-stage

Agenus是一家临床阶段的公司

immuno-oncology

免疫肿瘤学

company focussed on developing immune therapies for cancer.

公司专注于开发癌症的免疫疗法。

This acquisition will give Zydus access to advanced biologics manufacturing capabilities and enable the company to establish a key presence in California, a leading global biotechnology hub, it said.

该公司表示，此次收购将使 Zydus 获得先进的生物制品生产能力，并使其得以在加州建立重要影响力；加州是全球领先的生物技术中心。

'The acquisition will give Zydus a strategic foothold in the US for biologics manufacturing in the global hub for biotech innovation, California,” said Sharvil Patel, Managing Director, Zydus Lifesciences.

“此次收购将使Zydus在美国这个全球生物技术创新中心——加利福尼亚州——获得生物制品制造的战略立足点，”Zydus Lifesciences董事总经理Sharvil Patel表示。

Live Events

现场活动

“It will enhance our ability to partner with innovation-centric entities, advancing new products and prioritising patient-centric solutions. The move strengthens our long-term biologics vision and positions us to better serve the evolving needs of the global biopharmaceutical industry,' he added.

“它将增强我们与以创新为中心的实体合作的能力，推动新产品的发展，并优先考虑以患者为中心的解决方案。此举加强了我们的长期生物制品愿景，并使我们能够更好地服务于全球生物制药行业不断变化的需求，”他补充道。

The deal will also enable Zydus to leverage supply chain dynamics to expand its reach in the US and globally.

该交易还将使 Zydus 能够利用供应链动态，扩大其在美国和全球的覆盖范围。

Zydus’ contract development and manufacturing business will operate as an independent entity and house the acquired manufacturing capabilities.

Zydus的合同开发和制造业务将作为独立实体运营，并将收购的制造能力纳入其中。

Zydus will become an exclusive contract manufacturer for Agenus and will provide manufacturing services for clinical and commercial supply of two identified Phase-3 ready immuno-oncology products, Botensilimab (BOT) and Balstilimab (BAL).

Zydus将成为Agenus的独家合同制造商，为两种已确定的处于第三阶段的免疫肿瘤学产品Botensilimab（BOT）和Balstilimab（BAL）提供临床和商业供应的制造服务。

Zydus will also have the first right of negotiation to manufacture any of the future pipeline products developed by Agenus.

Zydus还将拥有对Agenus开发的任何未来管道产品制造的优先谈判权。

Separately, Zydus Lifesciences has entered into an agreement with Agenus Inc to commercialise the US company’s investigational cancer therapy combinations of botensilimab (BOT) and balstilimab (BAL) in India and Sri Lanka.

此外，Zydus Lifesciences 已与 Agenus Inc 达成协议，将在印度和斯里兰卡商业化推广该美国公司的在研癌症治疗组合 botensilimab（BOT）和 balstilimab（BAL）。

The therapies are designed to strengthen and sustain the immune system’s response against tumour cells.

这些疗法旨在增强和维持免疫系统对肿瘤细胞的反应。

Currently in advanced clinical trials, BOT and BAL have demonstrated significant clinical activity across nine cancer types in more than 1,200 patients, Zydus said in a statement.

Zydus公司在一份声明中表示，目前处于高级临床试验阶段的BOT和BAL在超过1200名患者中展现了对九种癌症类型的显著临床活性。

As a part of the agreement, Zydus will be responsible for clinical development and regulatory approvals of licensed products in these territories and will pay 5% royalty on net sales upon successful approval and commercialisation.

根据协议的一部分，Zydus 将负责这些区域内授权产品的临床开发和监管审批，并在成功获批和商业化后按净销售额支付 5% 的特许权使用费。

(You can now subscribe to our

（你现在可以订阅我们的

Economic Times WhatsApp channel

经济时报WhatsApp频道

)

)

(You can now subscribe to our

（你现在可以订阅我们的

Economic Times WhatsApp channel

经济时报 WhatsApp 频道

)

)